Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41591-024-02849-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comment on: Serial changes in metabolic dysfunction-associated steatotic liver disease after sleeve gastrectomy and their associations with abdominal adiposity: a prospective cohort study.
Surg Obes Relat Dis
December 2024
Division of Bariatric and Metabolic Surgery, University General Hospital of Patras, Patras, Greece.
Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH Database.
Adv Ther
December 2024
Novo Nordisk Inc., 800 Scudders Mill Rd, Plainsboro, NJ, 08536, USA.
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH), the progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), is linked to cardiometabolic risk factors such as obesity and type 2 diabetes (T2D). The rising prevalence of MASH and risk of hepatic and extra-hepatic complications emphasize the need for a better understanding of disease progression and associated outcomes. This study aimed to evaluate the incidence of, and demographic and clinical characteristics associated with, progression to MASH-related complications by disease severity in patients with non-cirrhotic MASH or MASH cirrhosis.
View Article and Find Full Text PDFNoninvasive assessment of hepatic steatosis grades by ultrasound derived fat fraction in metabolic dysfunction associated steatotic liver disease.
Sci Rep
December 2024
Department of Medical Ultrasound, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Abdominal Medical Imaging, Jinan, 250014, China.
To evaluate the diagnostic performance of ultrasound-derived fat fraction (UDFF) and clinical prediction models in assessing hepatic steatosis grades in MASLD patients, with liver biopsy as reference standard.A total of 85 obese patients who were found to have fatty liver by B-mode ultrasound and underwent UDFF measurement, with liver biopsy available, were enrolled. The diagnostic performance of UDFF, clinical prediction models including fatty liver index (FLI), hepatic steatosis index (HSI), ZheJiang University index (ZJU index) and lipid accumulation product (LAP) for hepatic steatosis was assessed.
View Article and Find Full Text PDFEditorial: Evaluating the Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia-Authors' Reply.
Aliment Pharmacol Ther
December 2024
Division of Gastroenterology, MASLD Research Center, University of California at San Diego, San Diego, California, USA.
Editorial: Evaluating the Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinemia.
Aliment Pharmacol Ther
December 2024
Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, University of Utah Health, Salt Lake City, Utah, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!